Date published: 2026-5-28

1-800-457-3801

SCBT Portrait Logo
Seach Input

Fnk Inhibitors

Fnk inhibitors represent a distinctive class of chemical entities that exert their effects by selectively modulating the enzymatic activity of Fnk enzymes. These enzymes, found ubiquitously in various cellular compartments, play a pivotal role in orchestrating intricate signaling cascades and cellular responses. Fnk inhibitors are meticulously designed molecules, often synthesized through complex organic synthesis routes, with the primary objective of binding tightly to the catalytic pocket of Fnk enzymes. This binding interaction disrupts the enzymes' ability to facilitate specific biochemical transformations, consequently influencing downstream pathways that Fnk enzymes participate in. The structural architecture of Fnk inhibitors can vary significantly, encompassing diverse chemical scaffolds and functional groups. Rational design and structure-activity relationship studies are integral in refining the potency and selectivity of these inhibitors, ensuring optimal interaction with the enzyme's active site. This meticulous approach not only enables a deeper comprehension of Fnk enzyme mechanisms but also uncovers potential avenues for manipulating cellular behavior. The development of Fnk inhibitors entails a multidisciplinary approach, often involving structural biology, computational modeling, and medicinal chemistry. Researchers delve into the three-dimensional structure of Fnk enzymes, deciphering their active sites and conformational dynamics. This knowledge serves as the foundation for designing inhibitors that can effectively mimic the natural substrates, leading to a precise fit within the enzyme's binding pocket. Computational tools aid in predicting the binding affinity and interaction patterns of these inhibitors, guiding subsequent iterations of inhibitor design.Ultimately, the exploration of Fnk inhibitors offers more than just a pharmacological perspective; it unveils the intricate regulatory networks that govern cellular functions. By perturbing Fnk enzymes' activity, researchers gain insights into the broader implications of these enzymes in cellular homeostasis, signal transduction, and intercellular communication. While the focus remains on deciphering the molecular intricacies of Fnk inhibition, the potential implications extend beyond the laboratory, hinting at novel approaches to manipulate cellular responses for various applications.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3Ks), showcasing unique interactions with the enzyme's active site. Its structure allows for specific binding, disrupting lipid signaling pathways crucial for cellular processes. The compound's reactivity is influenced by its ability to form covalent bonds with key residues, altering enzymatic activity and downstream signaling. This selective inhibition leads to distinct kinetic profiles, emphasizing its role in modulating cellular responses.

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

This inhibitor targets the BCR-ABL kinase, which is overactive in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs).

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Another BCR-ABL inhibitor used for CML and GISTs, with a broader spectrum of kinase inhibition compared to imatinib.

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
$87.00
$135.00
$293.00
$505.00
$3827.00
42
(0)

This inhibitor targets the epidermal growth factor receptor (EGFR) kinase.

Lapatinib ditosylate

388082-78-8sc-202205B
sc-202205
sc-202205A
5 mg
10 mg
25 mg
$49.00
$77.00
$117.00
15
(1)

A dual EGFR and HER2 inhibitor, used in breast cancer therapy when HER2 is overexpressed.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

A multi-kinase inhibitor targeting RAF, VEGFR, and PDGFR kinases, approved for advanced renal cell carcinoma and hepatocellular carcinoma.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$153.00
$938.00
5
(0)

Another multi-kinase inhibitor targeting VEGFR, PDGFR, KIT, and others, used in renal cell carcinoma and gastrointestinal stromal tumors.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$251.00
$500.00
$547.00
16
(1)

An inhibitor of Janus kinases (JAKs), used for myelofibrosis and polycythemia vera.

Ibrutinib

936563-96-1sc-483194
10 mg
$156.00
5
(0)

This inhibitor targets Bruton's tyrosine kinase (BTK), used for CLL, mantle cell lymphoma, and other B-cell malignancies.